Pfizer has filed for a partial modification of the current regulatory approval for the smoking cessation aid Champix (varenicline) in Japan to change its manufacturing method with the aim of lifting the ongoing suspension of its shipments.
According to the article, Pfizer plans to resupply Champix to markets around the world after a four-year hiatus due to nitroso-varenicline contamination.